Entacapone in the management of Parkinson’s disease

Bibliography

• TANNER CM: Epidemiology of Parkinson's disease. Neural. Chit. (1992) 10(2):317–329.
   Google Scholar
• HORNYKIEWICZ 0: Biochemical aspects of Parkinson's disease. Neurology (1998) 51(2, Suppl. 2):S2–S9.
   Google Scholar
• MOURADIAN MM: Recent advances inthe genetics and pathogenesis of Parkinson's disease. Neurology (2002) 58(2):179–185.
   PubMed Web of Science ®Google Scholar
• LAMBERT D, WATERS CH: Comparative tolerability of the newer generation antiparkinsonian agents. Drugs Aging (2000) 16(1):55–65.
   PubMed Web of Science ®Google Scholar
• WATERS C: Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. J. Am. Geriatr. Soc. (2000) 48(6):692–698.
   PubMed Web of Science ®Google Scholar
• WATERS C: Practical issues with COMT inhibitors in Parkinson's disease. Neurology (2000) 55(11, Suppl. 4):557–559.
   Google Scholar
• FAHN S: Tolcapone: COMT inhibition for the treatment of Parkinson's disease. Neurology (1998) 50(5, Suppl. 5):S1–S2.
   Google Scholar
• WATERS CH, KURTH M, BAILEY P et al.: Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology(1997) 49(3):665–671.
   PubMed Web of Science ®Google Scholar
• WATERS CH, KURTH M, BAILEY P et al.: Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. Neurology (1998) 50(5, Suppl. 5):S39–S45.
   Google Scholar
• RUOTTINEN HM, RINNE UK: Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin. Neuropharmacol (1996) 19(3):222–233.
   PubMed Web of Science ®Google Scholar
• CEDARBAUM JM: Clinical pharmacokinetics of anti-parkinsonian drugs. Clin. Pharmacokinet. (1987) 13(3):141–178.
   PubMed Web of Science ®Google Scholar
• SANDLER M, JOHNSON RD, RUTHREN CR, REID JL, CALNE DM: Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition. Nature (1974) 247:364–366.
   PubMed Web of Science ®Google Scholar
• CHASE TN: Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology (1998) 50 (Suppl.):S17–S25.
   Google Scholar
• RINNE UK: Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand. (1983) 95:19–26.
   Google Scholar
• KERANEN T, GORDIN A, KARLSSON M et al: Inhibition of soluble catechol-0-methyltransferase and single-dose pharma-cokinetics after oral and intravenous administration of entacapone. Eur: Clin. Pharmacol (1994) 46(2):151–157.
   Web of Science ®Google Scholar
• RUOTTINEN HM, RINNE UK: A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol (1996) 19(4):283–296.
   PubMed Web of Science ®Google Scholar
• HEIKKINEN H, SARAHEIMO M, ANTILA S, OTTOILA P, PENTIKAINEN PJ: Pharmacokinetics of entacapone, a peripherally acting catechol-0-methyl-transferase inhibitor, in man - a study using a stable isotope technique. Eur: Clin. Pharmacol (2001) 56:821–826.
   Google Scholar
• •Recent study of pharmacokinetic properties of entacapone in healthy volunteers.
   Google Scholar
• KAAKKOLA S, TERAVAINEN H, AHTILA S, RITA H, GORDIN A: Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology (1994) 44(1):77–80.
   PubMed Web of Science ®Google Scholar
• AHTILA S, KAAKKOLA S, GORDIN A et al.: Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin. Neuropharmacol (1995) 18(1):46–57.
   PubMed Web of Science ®Google Scholar
• KERANEN T, GORDIN A, HARJOLA VP et al: The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol (1993) 16(2):145–156.
   PubMed Web of Science ®Google Scholar
• KAAKKOLA S, TERAVAINEN H, AHTILA S et al.: Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Ear. Neurol. (1995) 2:341–347.
   Web of Science ®Google Scholar
• MYLLYLA VV, SOTANIEMI KA, ILLI A, SUOMINEN K, KERANEN T: Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Ear. Clin. Pharmacol (1993) 45(5):419–423.
   PubMed Web of Science ®Google Scholar
• NUTT JG, WOODWARD WR, BECKNER RIVI et al.: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology (1994) 44(5):913–919.
   PubMed Web of Science ®Google Scholar
• HEIKKINEN H, NUTT JG, LEWITT PA, KOLLER WC, GORDIN A: The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin. Neuropharmacol (2001) 24(3):150–157.
   PubMed Web of Science ®Google Scholar
• FAHN S, ELTON R, THE UPDRS DEVELOPMENT COMMITTEE: Unified Parkinson's disease Rating Scale. In: Recent Developments in ParkinsonS disease. Fahn S, Marsden CD, Goldstein M, Caine DB (eds), Macmillan Health Care Information, Florham Park, NJ, USA (1987):153–163.
   Google Scholar
• PARKINSON STUDY GROUP: Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol (1997) 42(5):747–755.
   PubMed Web of Science ®Google Scholar
• ••Pivotal double-blind, placebo-controlled,randomised, 24-week study in the US of the clinical effectiveness of entacapone in PD patients with motor fluctuations.
   Google Scholar
• RINNE UK, LARSEN JP, SIDEN A, WORM-PETERSEN J: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology (1998) 51(5):1309–1314.
   PubMed Web of Science ®Google Scholar
• ••Pivotal European double-blind, placebo-controlled, randomised, 6-month study of the response to entacapone in PD patients with motor fluctuations.
   Google Scholar
• PICCINI P, BROOKS DJ, KORPELA K, PAVESE N, KARLSSON M, GORDIN A: The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. NeuroL Neurosurg. Psychiatry(2000) 68(5):589–594.
   PubMed Web of Science ®Google Scholar
• OLANOW CW, KOLLER WC: An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology (1998) 50(3, Suppl. 3):S1–S57.
   Google Scholar
• •Overview of available treatment options for PD with recommendations for each pharmacotherapy according to clinical context.
   Google Scholar
• NUTT JG: Levodopa: rational and irrational pharmacology. Ann. Neurol (1994) 36(1):4–5.
   PubMed Web of Science ®Google Scholar
• SAWLE GV, BURN DJ, MORRISH PK et al.: The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology (1994) 44(7):1292–1297.
   PubMed Web of Science ®Google Scholar
• RUOTTINEN HM, RINNE JO, OIKONEN VJ et al.: Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-0-methyltransferase and monoamine wddase type B: differing response in relation to presynaptic dopaminergic dysfunction. Synapse (1997) 27:336–346.
   PubMed Web of Science ®Google Scholar
• •Positron emission tomography using 18F-dopa demonstrating increased accumulation of striatal 18E-dopa after entacapone administration in early PD patients.
   Google Scholar
• RUOTTINEN HM, NIINIVIRTA M, BERGMAN J et al.: Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires pro-longed imaging. Synapse (2001) 40:19–26.
   PubMed Web of Science ®Google Scholar
• •Use of prolonged imaging times by 18F-dopa PET to demonstrate increased striatal 18F-dopa uptake in advanced PD patients.
   Google Scholar
• FACTOR SA, MOLHO ES, FEUSTEL PJ, BROWN DL, EVANS SM: Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol (2001) 24(5):295–962 Expert Op/n. Pharmacother. (2002) 3(7)299.
   Google Scholar
• JORGA K: Pharmacokinetics, pharmacodynamics and tolerability of tolcapone: a review of early studies in volunteers. Neurology (1998) 50:S31–S38.
   Google Scholar
• ONOFRJ M, THOMAS A, IACONO D, DI IORIO A, BONANNI L: Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Ear: Neurol (2001) 46(1):11–16.
   PubMed Web of Science ®Google Scholar
• MYLLYLA VV, KULTALAHTI ER, HAAPANIEMI H, LEINONEN M: Twelve-month safety of entacapone in patients with Parkinson's disease. Ear: J. Neurol (2001) 8(1):53–60.
   PubMed Web of Science ®Google Scholar
• ILLI A, SUNDBERG S, OJALA-KARLSSON P, SCHEININ M, GORDIN A: Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Ear: J. Clin. Pharmacol (1996) 51(3-4):273–276.
   PubMed Web of Science ®Google Scholar
• ILLI A, SUNDBERG S, OJALA-KARLSSON P, SCHEININ M, GORDIN A: Simultaneous inhibition of catechol-0-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin. Pharmacol Ther (1996) 59(4):450–457.
   PubMed Web of Science ®Google Scholar
• LYYTINEN J, KAAKKOLA S, AHTILA S,TUOMAINEN P, TERAVAINEN H: Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Mov. Disord (1997) 12(4):497–505.
   PubMed Web of Science ®Google Scholar
• LYYTINEN J, KAAKKOLA S, GORDIN A, KULTALAHTI E-R, TERAVAINEN H: Entacapone and selegiline with L-dopa in patients with Parkinson's disease: an interaction study. Parkinsonism Relat. Disord. 6:215–222.
   Google Scholar
• ILLI A, SUNDBERG S, KOULU M, SCHEININ M, HEINAVAARA S, GORDIN A: COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int. J. Clin. Pharmacol Ther (1994) 32(11):582–588.
   PubMed Web of Science ®Google Scholar
• LYYTINEN J, SOVIJARVI A, KAAKKOLA S, GORDIN A, TERAVAINEN H: The effect of catechol-0-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-dopa-treated patients with Parkinson's disease. Clin. Neuropharmacol (2001) 24:50–57.
   PubMed Web of Science ®Google Scholar
• MYLLYLA VV, KULTALAHTI ER, HAAPANIEMI H, LEINONEN M: Twelve-month safety of entacapone in patients with Parkinson's disease. Eur: Neurol (2001) 8(1):53–60.
   Web of Science ®Google Scholar
• RENFREW C, DICKSON R, SCHWAB C: Severe hypertension following ephedrine administration in a patient receiving entacapone. Anesthesiology (2000) 93(6):1562.
   PubMed Web of Science ®Google Scholar
• GRAHAM JM, GRUNEWALD RA, SAGAR HJ: Hallucinosis in idiopathic Parkinson's disease. .1 Neurol Neurosurg. Psychiatry (1997) 63(4):434–440.
   Google Scholar
• NUIJTEN MJ, VAN IPEREN P, PALMER C, VAN HILTEN BJ, SNYDER E: Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health (2001) 4(4):316–328.
   PubMedGoogle Scholar